-
Views
-
Cite
Cite
Naxitamab-gqgk, American Journal of Health-System Pharmacy, Volume 78, Issue 9, 1 May 2021, Pages 758–761, https://doi.org/10.1093/ajhp/zxab035
- Share Icon Share
Extract
Naxitamab-gqgk is a glycolipid disialoganglioside (GD2)-binding monoclonal antibody antineoplastic agent.
Class: 10:00 • Antineoplastic Agents (AHFS primary) Brands: Danyelza®
...
Uses
Naxitamab-gqgk has the following uses:
...
Dosage and Administration
General.
Naxitamab-gqgk is available in the following dosage form(s) and strength(s): Concentrate for injection: 40 mg/10 mL (4 mg/mL) in a single-dose vial.
Dosage.
It is essential that the manufacturer’s labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Pediatric Patients.
Dosage and Administration.
The recommended dosage of naxitamab-gqgk is 3 mg/kg/day (up to 150 mg/day), administered as an intravenous infusion after dilution on days 1, 3, and 5 of each treatment cycle. Treatment cycles are repeated every 4 weeks until complete response or partial response, followed by 5 additional cycles every 4 weeks. Subsequent cycles may be repeated every 8 weeks.
Administer pre-infusion medications and supportive treatment, as appropriate, during infusion.
Comments